⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14480104 | 0.88 | — | — | |
| SCHEMBL126941 | 0.87 | — | — | |
| SCHEMBL436662 | 0.87 | — | — | |
| SCHEMBL607692 | 0.84 | CA1 (0.33) | — | |
| SCHEMBL211850 | 0.84 | — | — | |
| SCHEMBL609096 | 0.84 | CA1 (0.33) | — | |
| SCHEMBL2092698 | 0.80 | — | — | |
| SCHEMBL5509479 | 0.80 | — | — | |
| SCHEMBL5705227 | 0.73 | — | — | |
| SCHEMBL1476359 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064178-A1 | HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| US-20170209440-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS | CHDI FOUNDATION, INC. | 2017-07-27 | — | — | US | claimed |
| EP-3169684-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS | CHDI Foundation, Inc. (US) | 2017-05-24 | — | — | EP | claimed |
| WO-2016011316-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS | CHDI FOUNDATION, INC. (US) | 2016-01-21 | — | — | WO | claimed |
| US-8324257-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-02-18 | — | — | US | claimed |
| EP-2081918-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2009-07-29 | — | — | EP | claimed |
| WO-2008042928-A2 | OXADIAZOLE AND THIADIAZOLE DERIVATIVES AS MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2008-04-10 | — | — | WO | claimed |
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-118043323-A | Bicyclic derivative PARP inhibitors and uses thereof | 西藏海思科制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4351570-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | Ideaya Biosciences, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024074611-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-04-11 | — | — | WO | disclosed |
| EP-4347569-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | Ideaya Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-1997035845-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997001543-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
| EP-0714909-A1 | Composition for prophylaxis or treatment of pulmonary circulatory diseases | Takeda Chemical Industries, Ltd. (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0655463-A1 | Cyclic hexapeptides having endothelin antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| US-5158948-A | Treating neurological and psychological disorders | ABBOTT LABORATORIES (US) | 1992-10-27 | — | — | US | disclosed |